<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01637233</url>
  </required_header>
  <id_info>
    <org_study_id>MARCH-Kirby CNS</org_study_id>
    <secondary_id>2011-002107-15</secondary_id>
    <nct_id>NCT01637233</nct_id>
  </id_info>
  <brief_title>MARCH Central Nervous System Substudy</brief_title>
  <official_title>Maraviroc Switch Central Nervous System (CNS) Substudy: a Substudy of MARCH, a Randomised, Open-label Study to Evaluate the Efficacy and Safety of Maraviroc (MVC) as a Switch for Either Nucleoside or Nucleotide Analogue Reverse Transcriptase Inhibitors (N(t)RTI) or Boosted Protease Inhibitors (PI/r) in HIV-1 Infected Individuals With Stable, Well-controlled Plasma HIV-RNA While Taking Their First N(t)RTI + PI/r Regimen of Combination Antiretroviral Therapy (cART).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kirby Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kirby Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This substudy is a prospective, observational, open-label, randomised study within the MARCH
      study. The purpose of this substudy is to investigate the changes in cerebral function
      parameters at 5 timepoints over 96 weeks of the three different treatment arms within the
      MARCH study. The investigators hypothesise that there will be improvements in cerebral
      function in those patients randomised, as part of the parent study, into the maraviroc arms.

      the assessments in this CNS substudy will include:

        1. Neurocognitive function as assessed by a computerised testing battery called CogState;

        2. changes in cerebral metabolites as measured via 1H Magnetic Resonance Spectroscopy
           (1H-MRS)

      In those randomised to the maraviroc arms (arms 2 and 3) there is an optional Lumbar puncture
      at week 48. The cerebrospinal fluid will be used to measure maraviroc levels and an
      ultrasensitive CSF HIV-1 viral load. These results will be matched with levels in the plasma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      this is detailed above, this is a substudy of MARCH
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To assess changes in NC function over 96 weeks, measured via a computerised testing battery in HIV-infected subjects stable on antiretroviral therapy randomised to three different treatment approaches</measure>
    <time_frame>96 weeks</time_frame>
    <description>using CogState testing at 5 timepoints, weeks 0, 12, 24, 48, 96</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To assess changes in cerebral metabolites over 96 weeks, measured via 1H Magnetic Resonance Spectroscopy (1H-MRS), in HIV-infected subjects stable on antiretroviral therapy randomised to three different treatment approaches</measure>
    <time_frame>96 weeks</time_frame>
    <description>Assessment of CNS metabolites via 1H-MRS at week 0, 48, 96
Cerebral metabolites in frontal white and grey voxels, and basal ganglia will be measured
Measurable metabolites will include assessment of neuronal markers, N-acetyl-aspartate, and inflammatory markers, myo-Inositols and Choline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>to assess CSF HIV-1 RNA and CSF maraviroc concentration (in the MVC treatment arms) versus plasma HIV -1 RNA and MVC concentration after 48 weeks of therapy</measure>
    <time_frame>48 weeks</time_frame>
    <description>A LP examination at week 48 (optional and only in the MVC treatment arms, and only if there is no contraindication to LP) to assess, with matched plasma samples:
CSF MVC concentration
CSF HIV-1 RNA
CSF biomarkers</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">28</enrollment>
  <condition>HIV-1 Infection</condition>
  <arm_group>
    <arm_group_label>NRTI + PI</arm_group_label>
    <description>This is the randomisation of the main study, Arm 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>maraviroc + PI</arm_group_label>
    <description>this is the randomisation of the main study, Arm 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>maraviroc + NRTI</arm_group_label>
    <description>this is the randomisation of the main study, Arm 3</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arm 1 TNucleotide Analogue Reverse Transcriptase Inhibitors and Boosted Protease Inhibitors</intervention_name>
    <description>NRTI+PI</description>
    <arm_group_label>NRTI + PI</arm_group_label>
    <other_name>tenofovir</other_name>
    <other_name>emtricitabine</other_name>
    <other_name>zidovudine</other_name>
    <other_name>lamivudine</other_name>
    <other_name>abacavir</other_name>
    <other_name>Ritonavir</other_name>
    <other_name>lopinavir</other_name>
    <other_name>darunavir</other_name>
    <other_name>atazanavir</other_name>
    <other_name>fosamprenavir</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arm 2 Maraviroc and Protease Inhibitors</intervention_name>
    <description>maraviroc + PI</description>
    <arm_group_label>maraviroc + PI</arm_group_label>
    <other_name>maraviroc</other_name>
    <other_name>Ritonavir</other_name>
    <other_name>lopinavir</other_name>
    <other_name>darunavir</other_name>
    <other_name>atazanavir</other_name>
    <other_name>fosamprenavir</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arm 3 Maraviroc and Nucleotide Analogue Reverse Transcriptase Inhibitors</intervention_name>
    <description>maraviroc + NRTI</description>
    <arm_group_label>maraviroc + NRTI</arm_group_label>
    <other_name>maraviroc</other_name>
    <other_name>tenofovir</other_name>
    <other_name>emtricitabine</other_name>
    <other_name>zidovudine</other_name>
    <other_name>lamivudine</other_name>
    <other_name>abacavir</other_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      plasma and CSF
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        participants in the MARCH main study who are eligible for the CNS substudy and provide
        written informed consent for participation
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provision of written, informed consent for participation in the substudy

          -  Enrolled into the substudy either at or before the week 0 visit of the main study

        Exclusion Criteria:

          -  Pre-existing CNS diseases

          -  Recent head injury (past three months)

          -  Current history of major depression or psychosis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alan Winston, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Imperial Healthcare, London, UK</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Ramos Mejía</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1221ADC</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundación IDEAA</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1405CKC</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CAICI</name>
      <address>
        <city>Rosario</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chulalongkorn University Hospital</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brighton &amp; Sussex University NHS Trust</name>
      <address>
        <city>Brighton</city>
        <state>Sussex</state>
        <zip>BN21ES,</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Imperial Healthcare, St. Mary's Hospital</name>
      <address>
        <city>London</city>
        <zip>W2</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Thailand</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>France</country>
    <country>Mexico</country>
  </removed_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 27, 2012</study_first_submitted>
  <study_first_submitted_qc>July 10, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2012</study_first_posted>
  <last_update_submitted>January 18, 2016</last_update_submitted>
  <last_update_submitted_qc>January 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV-1 infection</keyword>
  <keyword>neurocognitive function</keyword>
  <keyword>switch study</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Lopinavir</mesh_term>
    <mesh_term>Darunavir</mesh_term>
    <mesh_term>Atazanavir Sulfate</mesh_term>
    <mesh_term>HIV Protease Inhibitors</mesh_term>
    <mesh_term>Fosamprenavir</mesh_term>
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
    <mesh_term>Zidovudine</mesh_term>
    <mesh_term>Maraviroc</mesh_term>
    <mesh_term>Abacavir</mesh_term>
    <mesh_term>Protease Inhibitors</mesh_term>
    <mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

